Company Profile For Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories. The Company has a pharmaceutical business, whose principal products are Copaxone for multiple sclerosis and Azilect for Parkinson’s disease and respiratory products. Teva’s active pharmaceutical ingredient business provides vertical integration to Teva’s own pharmaceutical production and sells to third party manufacturers. The Company’s global operations are conducted in North America, Europe, Latin America, Asia and Israel. Teva has operations in more than 60 countries, as well as 38 finished dosage pharmaceutical manufacturing sites in 17 countries, 20 generic research and development centers operating mostly within certain manufacturing sites and 20 API manufacturing sites around the world. In January 2009, Phibro Animal Health Corporation completed the acquisition of the Abic Animal Health business from the Company.

BRIEF: For the nine months ended 30 September 2008, Teva Pharmaceutical Industries Limited's revenue increased 23% to $10.1B. Net income increased 24% to $1.62B. Revenues reflect an increase in sales of Pharmaceutical products. Net income also reflects a lower tax burden per dollar of taxable income, partially offset by higher cost of sales, research & development and financial expenses. Earnings also reflects lower attribute to non-controlling interests.